Nomads
9.5.2023 12:31:45 CEST | ACCESS Newswire | Press release
BANGKOK / ACCESSWIRE / May 9, 2023 / HOYA Vision Care, a leader in optical technology innovation, continues to roll out the MiYOSMART sun range, with a planned reach of 30 countries, over the next few months following the soft launch in April 2023. The photochromic spectacle lenses, MiYOSMART Chameleon, and polarised spectacle lenses, MiYOSMART Sunbird, were developed to slow down myopia progression in children using D.I.M.S. Technology while providing protection from intense sunlight.[1-5] These two new products, along with the MiYOSMART clear spectacle lenses which launched in 2018, give children the freedom to comfortably take part in the activities they enjoy indoors and outdoors without compromising their eyesight.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Sun protection for children
MiYOSMART Chameleon and MiYOSMART Sunbird both provide protection from intense sunlight while simultaneously correcting the myopic refractive error and slowing myopia progression.[1-5] The new spectacle lenses utilise the same D.I.M.S. Technology used in the award-winning [6,7] and noninvasive MiYOSMART clear spectacle lenses, shown to slow myopia progression by 60% in children aged 8 to 13.[3] Due to its HOYA photochromic lens technology, MiYOSMART Chameleon is an all-in-one solution to myopia management and protected outdoor activity. It rapidly adapts to the level of sunlight and fades back to clear indoors in seconds.[8] Meanwhile, MiYOSMART Sunbird is the ideal addition to MiYOSMART clear spectacle lenses for extra protection from intense sunlight and glare.[1,9,10] It also offers vibrant colours and rich contrast in bright light, allowing children to fully experience the beauty of outdoors.[11]
"Children's vision is worth protecting. By acting today, we give them more opportunity tomorrow," said Frederiek Ysebaert, Managing Director of the Pediatric Care Business Unit at HOYA Vision Care. "With the launch of MiYOSMART sun spectacle lenses, inspired by our discussions with eye care professionals, we can enable children across the world to spend more time outdoors while protecting their eyes from intense sunlight, maximising the benefits of D.I.M.S. Technology on myopia progression."
Alongside the launch of the MiYOSMART sun range, HOYA Vision Care will launch "protect how they see the world," a dedicated global campaign to raise awareness of the importance of outdoor time and sun protection in children. Spending time outdoors may slow down myopia progression in children[6,7], and as such it is the most common recommended behavioural management for myopia given by eye care professionals.[8] However, as the majority of lifetime sun exposure occurs under the age of 21, it is necessary to prevent long-term eye damage to children's eyes with effective and reliable sun protection.[1,9] This is particularly important for myopic children using atropine eyedrops for myopia management, and those that are light-sensitive.[2,10,11]
From the launch in 2018 until the end of 2022, over four million MiYOSMART spectacle lenses were purchased by parents across the world.[18] With the launch of MiYOSMART Chameleon and MiYOSMART Sunbird, HOYA Vision Care will continue to help fight and control the growing problem of myopia around the world.
Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.
About HOYA Vision Care
For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology innovation. As a manufacturer of high-quality, high-performing eyeglass lenses, HOYA continuously aims to bring the best possible vision care solutions to eye care professionals and their patients around the world. The company supplies lenses in 110 countries with a network of over 17,000 employees and 43 laboratories around the globe.
References
1. WSPOS. Sunlight Exposure & Children's Eyes Consensus Statement. 2016. Available at: https://www.wspos.org/wspos-sunlight-exposure-childrens-eyes-consensus-statement/ (Last accessed 28/03/2023)
2. Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019;33(1):3-13.
3. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368.
4. Lakkis C, Weidemann K. Evaluation of the performance of photochromic spectacle lenses in children and adolescents aged 10 to 15 years. Clin Exp Optom. 2006;89(4):246-252. .
5. Renzi-Hammond LM, Hammond BR Jr. The effects of photochromic lenses on visual performance. Clin Exp Optom. 2016;99(6):568-574.
6. Winners of the exhibition's grand prix. Inventions Geneva. N.D. Available from: https://inventions-geneva.ch/en/winners/ (Last accessed 28/03/2023)
7. Winners 2020. Silmo Paris. 2020. https://en.silmoparis.com/SILMO-d-OR/SILMO-dOrAwards/2020-Winners# (Last accessed 28/03/2023).
8. Hoya data on file. HOYA Internal Product Performance Validation. 09/2022
9. Hoya data on file. UVA and UVB transmittance for MiYOSMART photochromic and polarized sun spectacle lenses. 07/2022
10. Hoya data on file. Luminous transmittance for MiYOSMART polarized sun spectacle lenses. 07/2022
11. Quintana MS, Langa A, del Moral-Martinez I, et al. Polarized Filters Enhance Contrast Sensitivity When Glare Is Produced On A Flat Surface Under Photopic Conditions. Invest Ophthalmol Vis Sci. 2006;47(13):1225.
12. Ho CL, Wu WF, Liou YM. Dose-Response Relationship of Outdoor Exposure and Myopia Indicators: A Systematic Review and Meta-Analysis of Various Research Methods. Int J Environ Res Public Health. 2019;16(14):2595.
13. Jonas JB, Ang M, Cho P, et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci. 2021;62(5):6.
14. WSPOS. Myopia Survey Data. November 2022. Presented as part of WSPOS Symposium: Comprehensive Update on Myopia Management.19-20 November 2022. Available from: http://forum.wspos.org/symposium-part-1-comprehensive-update-on-myopia-management-2
15. Prevent Blindness. Children's Eyes are More Susceptible to Long-Term Damage from UV Rays. 2011. Available at: https://preventblindness.org/childrens-eyes-are-more-susceptible-to-longtermdamage-from-uv-rays/ (Last accessed 28/03/2023)
16. Li FF, Yam JC. Low-Concentration Atropine Eye Drops for Myopia Progression. Asia Pac J Ophthalmol (Phila). 2019;8(5):360-365.
17. Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017;135(6):624-630.
18. Based on number of MiYOSMART lenses sold as per Hoya sales data on file as of December 2022.
Contact Information
Susan Brown
PR Lead
susan@wearenomads.com
8312334616
Related Images
SOURCE: HOYA Vision Care
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/753658/HOYA-Vision-Care-Launches-MiYOSMART-Sun-Spectacle-Lenses-Combining-Protection-From-Intense-Sunlight-With-Myopia-Management
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q213.11.2026 13:30:00 CET | Press release
MIAMI, FL / ACCESS Newswire / November 13, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) ("Digi Power X" or the "Company"), an AI data center infrastructure operator, today reported its financial and operating results for the third quarter ended September 30, 2026 (all amounts in U.S. dollars, unless otherwise indicated). The Company's quarterly report on Form 10-Q, which includes unaudited consolidated financial statements and management's discussion and analysis ("MD&A") for the quarter ended September 30, 2026, is being filed and made accessible under the Company's continuous disclosure profile on SEDAR+ at www.sedarplus.ca and will also be available on EDGAR at www.sec.gov/edgar. Third Quarter 2026 Highlights All amounts in U.S. dollars (millions) Revenue of $12.25 million, up 85% from the previously completed fiscal quarter and an increase of 50% compared to the quarter ended September 30, 2025; $119.6 million in cash, cash equivalents and digital currencies, $103.0 mill
Fermi Announces New Agreements with Investment-Grade Hyperscaler and Third Quarter 2026 Financial Results12.11.2026 13:00:00 CET | Press release
DALLAS, TX / ACCESS Newswire / November 12, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced its third quarter 2026 financial results and multiple new agreements with an investment-grade hyperscaler to advance 600 megawatts ("MW") of power capacity at Project Matador. A conference call is scheduled for 9 a.m. Eastern Time / 2 p.m. British Time today, November 12, 2026. Accompanying slides and prepared remarks can be found at https://investor.fermiamerica.com. Participation details are included in this release. "Hyperscalers want sites that are ready with permitted power, and Fermi's Project Matador is one of few that can meet that demand today," said Lee McIntire, Fermi Chief Executive Officer. "Our headstart in speed to power is a key reason an investment-grade hyperscaler has signed up for 600 megawatts and committed more than $200 million up front to accelerate construction at Project Matador with an additional $90 mi
Nexteer Announces First Share Repurchase Programme of Up to US$60 Million12.11.2026 01:40:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / November 11, 2026 / Nexteer Automotive today announced that its Board of Directors has approved, the Company's first share repurchase programme of up to US$60 million, equivalent to approximately HK$471 million. The programme reflects the Board's confidence in Nexteer's business and long-term prospects. The Group's strong liquidity position supports returning capital to shareholders while continuing to invest in the business and its future development. Disciplined Capital Allocation The programme complements Nexteer's dividend distributions and represents a further step in returning capital to shareholders. It follows the dividend paid out in July 2026 of approximately US$46 million, representing 45% of the Company's net income attributable to shareholders for the year ending December 31, 2025 -and the highest dividend payout ratio in the Company's history. Nexteer remains committed to disciplined capital allocation, balancing investment in the busines
GoodData.AI Launches the Agentic Serving Plane, a New Category of Enterprise Data Infrastructure for AI Agents10.11.2026 15:30:00 CET | Press release
SAN FRANCISCO, CA / ACCESS Newswire / November 10, 2026 / GoodData.AI, the open agentic analytics platform, today launched the Agentic Serving Plane, a governed execution layer designed for the high-concurrency, context-rich data workloads created by AI agents. The Agentic Serving Plane sits between enterprise data platforms and the applications, analytics experiences and agents that consume them. It provides workload serving, business semantics, contextual grounding, access control, and AI execution services through a common governed layer. The current enterprise data infrastructure was designed primarily for humans: occasional queries, predictable workloads, and access by known users. AI agents operate differently. A single business task can generate tens or hundreds of short-lived data operations as an agent investigates, reasons, and decides what to ask next. When many agents operate simultaneously, intermittent human querying becomes continuous, high-concurrency agentic demand. Ag
Envision Pharma Group appoints Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian10.11.2026 15:00:00 CET | Press release
FAIRFIELD, CT / ACCESS Newswire / November 10, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, has appointed Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian. Siino will lead a team providing best-in-class launch and revenue management services to the biopharma community. Pharma and biotech companies across the industry seek suppliers who can support them from their earliest stages, often before they have built in-house commercial, market access, and revenue management capabilities. Two Labs provides commercialization services and consulting support as these companies prepare for and execute successful launches; Riparian offers consulting, managed services, and technology to manage and protect revenue as their therapies reach patients. Together, Envision's Two Labs and Riparian businesses offer a single, connected solution spanning launch and beyond. Under Siino's leadership, clients wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
